These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 2884189)

  • 1. Nabumetone (BRL 14777) presystemic elimination and disposition in patients with liver impairments.
    Terziivanov D; Maleev A; Vlahov V
    Int J Clin Pharmacol Ther Toxicol; 1987 Apr; 25(4):208-13. PubMed ID: 2884189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver insufficiency as a factor modifying the pharmacokinetic characteristic of the preparation nabumetone.
    Maleev A; Vlahov V; Gruev I; Dierdorf D; Kostova N; Bacracheva N
    Int J Clin Pharmacol Ther Toxicol; 1986 Aug; 24(8):425-9. PubMed ID: 3759278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disposition and excretion of 6-methoxy-2-naphthylacetic acid, the active metabolite of nabumetone in horses.
    Soma LR; Uboh CE; Rudy JA; Smith MS
    Am J Vet Res; 1996 Apr; 57(4):517-21. PubMed ID: 8712517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An overview of the clinical pharmacokinetics of nabumetone.
    Hyneck ML
    J Rheumatol Suppl; 1992 Nov; 36():20-4. PubMed ID: 1474531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Penetration of the active metabolite of nabumetone into synovial fluid and adherent tissue of patients undergoing knee joint surgery.
    Miehlke RK; Schneider S; Sörgel F; Muth P; Henschke F; Giersch KH; Münzel P
    Drugs; 1990; 40 Suppl 5():57-61. PubMed ID: 2081495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extractionless determination of 6-methoxy-2-naphthylacetic acid, a major metabolite of nabumetone, in human plasma by high-performance liquid chromatography.
    de Jager AD; Hundt HK; Hundt AF; Swart KJ; Knight M; Roberts J
    J Chromatogr B Biomed Sci Appl; 2000 Apr; 740(2):247-51. PubMed ID: 10821411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of carbonyl reducing enzymes in the phase I biotransformation of the non-steroidal anti-inflammatory drug nabumetone in vitro.
    Skarydova L; Nobilis M; Wsól V
    Xenobiotica; 2013 Apr; 43(4):346-54. PubMed ID: 23020786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nabumetone pharmacokinetics in patients with varying degrees of renal impairment.
    Boelaert JR; Jonnaert HA; Daneels RF; Schurgers ML; Thawley AR; Undre NA; Cooper DL
    Am J Med; 1987 Oct; 83(4B):107-9. PubMed ID: 3687998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nabumetone--a novel anti-inflammatory drug: the influence of food, milk, antacids, and analgesics on bioavailability of single oral doses.
    von Schrader HW; Buscher G; Dierdorf D; Mügge H; Wolf D
    Int J Clin Pharmacol Ther Toxicol; 1983 Jun; 21(6):311-21. PubMed ID: 6688407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of nabumetone, a new non-steroidal anti-inflammatory drug, on urinary prostaglandin excretion in man.
    Giannessi D; Lazzerini G; Filipponi P; Mannarelli C; Vaiani G; Grossi E; De Caterina R
    Pharmacol Res; 1993; 28(3):229-41. PubMed ID: 8108313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood and tissue fluid levels of a new non-steroidal anti-inflammatory preparation of nabumetone.
    Torre D; Sampietro C; Maggiolo F
    J Int Med Res; 1987; 15(6):368-73. PubMed ID: 3436484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical overview of nabumetone. Pharmacology, bioavailability, metabolism, and toxicology.
    Mangan FR; Flack JD; Jackson D
    Am J Med; 1987 Oct; 83(4B):6-10. PubMed ID: 3688000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Penetration of nabumetone into inflammatory exudates in the rat.
    Haddock RE; Jeffery DJ; Mangan FR; Pardon IS
    J Pharm Pharmacol; 1983 Jun; 35(6):358-62. PubMed ID: 6135773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nabumetone kinetics in the young and elderly.
    McMahon FG; Vargas R; Ryan JR; Fitts DA
    Am J Med; 1987 Oct; 83(4B):92-5. PubMed ID: 3688002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose adjustment in patients with liver disease.
    Delcò F; Tchambaz L; Schlienger R; Drewe J; Krähenbühl S
    Drug Saf; 2005; 28(6):529-45. PubMed ID: 15924505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nabumetone--a novel anti-inflammatory drug: bioavailability after different dosage regimens.
    von Schrader HW; Buscher G; Dierdorf D; Mügge H; Wolf D
    Int J Clin Pharmacol Ther Toxicol; 1984 Dec; 22(12):672-6. PubMed ID: 6526543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-inflammatory and gastrointestinal effects of nabumetone or its active metabolite, 6MNA (6-methoxy-2-naphthylacetic acid): comparison with indomethacin.
    Melarange R; Gentry C; O'Connell C; Blower PR; Neil C; Kelvin AS; Toseland CD
    Agents Actions; 1992; Spec No():C82-3. PubMed ID: 1442340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [6-methoxy-2-naphthylacetic acid level in plasma, synovial fluid and adjacent tissue in patients with rheumatoid arthritis or gonarthroses after a 4-day therapy with nabumetone (Arthaxan)].
    Miehlke RK; Schneider S; Sörgel F; Muth P; Henschke F; Fedder M
    Z Rheumatol; 1991; 50(2):103-8. PubMed ID: 1872041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of isoxicam in hepatic disease.
    Ferry N; Cuisinaud G; Ouzan D; Trepo C; Sassard J
    Br J Clin Pharmacol; 1986; 22 Suppl 2(Suppl 2):143S-147S. PubMed ID: 2887185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolism of nabumetone (BRL 14777) by various species including man.
    Haddock RE; Jeffery DJ; Lloyd JA; Thawley AR
    Xenobiotica; 1984 Apr; 14(4):327-37. PubMed ID: 6464502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.